Evaluation and Management of Persistent Oral Candidiasis After Nystatin Therapy

Clinical Assessment

• Re‑examination of the oral cavity for persistent white plaques, erythema, or angular cheilitis should be performed to identify inadequate response to prior nystatin therapy. 1
• A diagnostic trial of systemic fluconazole (100–200 mg daily for 7–14 days) is recommended for moderate‑to‑severe oropharyngeal candidiasis and can both confirm and treat residual infection. 3
• Underlying immunosuppressive conditions (e.g., HIV with CD4 < 200 cells/µL, uncontrolled diabetes, chronic steroid use, or malignancy) must be assessed because they markedly increase the risk of recurrent oral candidiasis. 4
• In denture wearers, inadequate denture disinfection can sustain candidal colonization and contribute to dysgeusia; proper disinfection should be instituted. 3

Treatment of Active Candidiasis

• The mild‑disease regimen of clotrimazole troches is supported by clinical evidence for effective symptom resolution. 2
• Fluconazole dosing of 100–200 mg daily is endorsed for moderate‑to‑severe disease and serves both therapeutic and diagnostic purposes. 3
• Concurrent denture disinfection is essential to eradicate the reservoir of Candida in denture wearers. 3

Management When No Active Infection Is Identified

• A short trial of oral fluconazole can be used to exclude persistent candidiasis; if symptoms resolve, no further antifungal therapy is required. 1

Chronic Suppressive Antifungal Therapy

• Suppressive antifungal therapy is generally unnecessary; it is considered only when patients experience ≥ 4 episodes of oral candidiasis per year, in which case fluconazole 100 mg three times weekly is recommended. 3

Antifungal Stewardship

• Empiric long‑term antifungal therapy should be avoided in the absence of documented infection to prevent the development of antifungal resistance. 4